Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study

INTRODUCTION: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) improve hepatic dysfunction, although studies focusing on their underlying mechanisms are lacking, especially ones on dapagliflozin and empagliflozin. Here, we investigated the relationship between amelioration of hepatic dysfunction...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabetes Ther
Main Authors: Lee, Paul Chi Ho, Gu, Yunjuan, Yeung, Man Yi, Fong, Carol Ho Yi, Woo, Yu Cho, Chow, Wing Sun, Tan, Kathryn, Lam, Karen Siu Ling
Formato: Artigo
Idioma:Inglês
Publicado: Springer Healthcare 2018
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801241/
https://ncbi.nlm.nih.gov/pubmed/29322486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-017-0355-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares